1. Home
  2. Insights
  3. Blog
  4. Smart bioanalytical strategies for flow cytometry in clinical trials

Smart bioanalytical strategies for flow cytometry in clinical trials

As clinical development becomes increasingly complex, sponsors face growing pressure to generate robust biological evidence while accelerating decision-making across the development lifecycle. Biomarker strategies play a pivotal role in this process, helping researchers understand whether an investigational therapy is achieving its intended effect, identify potential safety signals, and support critical dose selection decisions.

Among the available technologies, flow cytometry has emerged as one of the most powerful tools for translational research and clinical development. By enabling detailed characterisation of cellular populations at the single-cell level, flow cytometry provides valuable insights into both therapeutic activity and immune system responses across a wide range of indications, including oncology, autoimmune disorders, and rare diseases. 

The value of developing biomarker strategies early

One of the most common challenges sponsors face is determining the right biomarker strategy for their clinical programme. The optimal approach depends on multiple factors, including disease biology, mechanism of action, therapeutic target, and operational considerations.

As development costs continue to rise, there is significant advantage in engaging biomarker and bioanalytical experts early in study planning. Early scientific input can help ensure that biomarker strategies are biologically relevant, operationally feasible, and aligned with clinical objectives.

Several flow cytometry-based approaches have become particularly valuable in immunotherapy development:

  • Immune cell immunophenotyping

    Monitoring host immune responses through leukocyte immunophenotyping remains a cornerstone of drug development. For example, investigational therapies may alter regulatory T-cell populations, potentially impacting immune homeostasis and patient safety. Flow cytometric assays utilising fluorochrome-conjugated monoclonal antibodies against markers such as CD4, CD25, and FoxP3 enable accurate monitoring of these critical immune cell subsets in peripheral blood samples. High parameter flow cytometry also supports the development of larger panels (>18 colors), allowing for deeper phenotyping of immune cell populations.

  • Receptor occupancy assays

    Receptor occupancy assays quantify the proportion of drug bound to target receptors on specific cell populations and may serve as an important pharmacodynamic indicator of drug activity. These assays can provide valuable insight into dose-response relationships and support the optimisation of dosing strategies throughout clinical development.

  • Rare event analysis

    Flow cytometry remains the gold standard for identifying and characterising extremely low-frequency cell populations within complex biological samples. Successful rare event analysis requires careful assay design, including consideration of background noise, fluorochrome brightness, resolution sensitivity, event frequency, and donor-to-donor variability.

  • Activation assays

    For therapies aimed at blocking immune cell activation, flow cytometry can be used to measure downstream mediators of activation. ICON has developed assays to measure the more transient events that occur during activation (ex. phosphorylation of kinases), as well as the synthesis of proteins involved in cell proliferation and cytokine release.

    Collectively, these assays provide additional information on the pharmacodynamic properties of a drug and can be used to inform decision making for later phase clinical trials.

Supporting better decisions in early phase studies

Early clinical development is fundamentally about reducing uncertainty. Sponsors need evidence that a therapy is engaging its target, delivering the expected biological effect, and doing so safely. Generating this evidence requires tools capable of translating complex biological interactions into actionable clinical insights.

Flow cytometry is one of the most powerful translational tools available to achieve this goal. It generates critical mechanistic and pharmacodynamic data that can reduce development risk and support more informed decision-making. By providing detailed characterisation of immune cell populations and functional responses, well-designed flow cytometry assays help sponsors answer key questions that influence the success of a development program including:

  • Confirming mechanism of action

    A fundamental objective of early phase studies is to demonstrate that an investigational therapy engages its intended biological target and produces the expected downstream effects. Flow cytometry enables comprehensive cellular and molecular characterisation, providing direct evidence of target engagement, immune modulation, and pharmacodynamic activity. These insights strengthen confidence in the therapeutic mechanism while identifying potential development risks early in the clinical program.

  • Detecting unintended off-target effects

    Early assessment of safety is equally important. Immunophenotyping assays can identify unintended changes in critical immune cell subsets and functional pathways before they manifest as clinically significant adverse events. Detecting these biological signals early enables sponsors to make timely, evidence-based decisions regarding study design, dose optimisation, or program progression, helping to reduce both patient risk and development uncertainty.

  • Enabling more informed dose selection

    Flow cytometry also provides quantitative biomarkers that support dose optimisation. Receptor occupancy and related pharmacodynamic assays can characterise the relationship between drug exposure, target engagement, and biological response. Integrating these data with pharmacokinetic and clinical endpoints helps define dose ranges that maximise therapeutic activity while minimising unnecessary exposure, supporting more rational dose selection for subsequent clinical development.

Why global standardisation matters for flow cytometry studies

As studies become larger and more geographically dispersed, maintaining assay consistency becomes increasingly challenging.

Robust flow cytometry assays depend on comprehensive qualification and validation programmes that assess precision, reproducibility, stability, and long-term performance. Factors such as analyst variability, instrument comparability, and inter-laboratory consistency must all be carefully evaluated.

For global trials, harmonised workflows, standardised instrument configurations, rigorous quality control procedures, and ongoing cross-site performance monitoring are essential to support the generation of accurate, reproducible, and reliable data under routine testing conditions.

Overcoming the challenge of sample stability

Sample stability remains one of the most significant operational considerations for flow cytometry studies, particularly in multinational clinical trials where samples may require extended transportation. Sponsors can address this challenge through two primary approaches:

1. Reducing sample transit times

Locating bioanalytical testing facilities closer to clinical sites can help minimise shipping durations and preserve sample integrity. Strategic laboratory networks are increasingly important for supporting global studies while maintaining data quality.

2. Optimising sample handling and storage

Additional opportunities exist to extend sample stability through evaluation of collection tubes, storage temperatures, cryopreservation approaches, and peripheral blood mononuclear cell (PBMC) isolation strategies. These considerations can significantly improve assay performance, particularly for studies involving challenging logistics. 

How early scientific collaboration creates long-term value

The growing complexity of modern clinical trials demands closer collaboration between sponsors and scientific partners. While specialist expertise is often brought in during later stages of development, some of the most important opportunities to optimise biomarker strategies occur much earlier.

Bringing bioanalytical, translational science, and operational experts into protocol development discussions can help improve assay feasibility, strengthen data quality, and ensure biomarker strategies are aligned with study objectives from the outset.

Ultimately, a well-designed and robust flow cytometry strategy does more than generate data. It helps sponsors make better decisions, reduce development risk, and maximise the value of every clinical study.

ICON combines decades of experience in translational science, biomarker development, and global clinical trial execution to design fit-for-purpose flow cytometry solutions aligned with each study’s objectives, mechanism of action, and regulatory strategy.

Rather than applying standardised assay panels, ICON works collaboratively with sponsors to select clinically relevant biomarkers and analytical approaches that generate meaningful insights while avoiding unnecessary assay complexity. This strategic approach helps sponsors accelerate decision-making, optimise development resources, and maximise the value of biomarker data throughout the clinical development lifecycle.

Find out more
In this section

Connect with us